You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. ROCKET PHARMACEUTICALS INC

Rocket Pharmaceuticals Inc XNAS: RCKT

Rocket Pharmaceuticals Inc Live Share Price Today, Share Analysis and Chart

Download real time

7.08 0.11 (1.58%)

73.76% Fall from 52W High

1.6M XNAS Volume

XNAS 23 Apr, 2025 12:41 PM (EDT)

Watchlist

Portfolio

Share

Rocket Pharmaceuticals Inc Key Metrics

Select

Market Capitalization

Below industry Median
754.9

PE TTM

Negative PE TTM
-2.9

PEG TTM

High in industry
0.5

Price to Book

Below industry Median
1.6

Institutional holding current Qtr %

High in industry
105.6

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-1.1

Net Profit TTM Growth %

Negative Net Profit TTM Growth %
-5.4

Piotroski Score

Below industry Median
2

Rel Perf vs Sector quarter%

-32.3

ROE Annual %

Negative ROE Annual %
-54.1

RoA Annual %

Negative RoA Annual %
-47.3
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Not Eligible
-
Valuation Score
Expensive Valuation
8.3 / 100
Momentum Score
Technically Bearish
23.5 / 100
Analyst Price Target
No estimates available

8

S

11

W

5

O

0

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Rocket Pharmaceuticals Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Rocket Pharmaceuticals Inc Stock Analysis

Rocket Pharmaceuticals Inc stock analysis with key metrics, changes, and trends.

Rocket Pharmaceuticals Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Net Profit$258.75 M5.35%negative

Annual Net Profit fell 5.35% in the last year to $258.75 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

Price to Earning Ratio-2.92-negative

Price to Earning Ratio is -2.92, which is negative.

Stock Price$7.08-70.34%negative

Stock Price fell 70.34% and underperformed its sector by 79.73% in the past year.

Quarterly Net profit$60.33 M1.12%negative

Quarterly Net profit fell 1.12% YoY to $60.33 M. Its sector's average net profit growth YoY for the quarter was -41.97%.

Debt to Equity Ratio0.06-positive

Debt to Equity Ratio of 0.06 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-54.14 %-54.14%negative

Return on Equity(ROE) for the last financial year was -54.14%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding54.12 %0.37%positive

Mutual Fund Holding increased by 0.37% in the last quarter to 54.12.

Promoter Share Holding3.36 %0.72%positive

Promoter Share Holding increased by 0.72% in the most recent quarter to 3.36%.

Interest Coverage Ratio-136.19-negative

Interest Coverage Ratio is -136.19, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding105.65 %0.14%positive

Institutional Holding increased by 0.14% in the last quarter to 105.65.

VIEW LESS


Loading data..

Rocket Pharmaceuticals Inc - Company Profile

What does Rocket Pharmaceuticals Inc do?

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Rocket Pharmaceuticals Inc Management structure

All Gross Remunerations are in USD
Ms. Sarbani Chaudhuri
Chief Commercial and Medical Affairs Officer
-
2025
Gross Remuneration
Year

Rocket Pharmaceuticals Inc Board of directors

All Gross Remunerations are in USD
Dr. Naveen Yalamanchi, M.D.
Independent Director
-
2025
Gross Remuneration
Year
Mr. Piratip Pratumsuwan
Director
-
2025
Gross Remuneration
Year

Rocket Pharmaceuticals Inc FAQ

How is Rocket Pharmaceuticals Inc today?
Rocket Pharmaceuticals Inc today is trading in the green, and is up by 1.58% at 7.08.
Rocket Pharmaceuticals Inc is currently trading up 1.58% on an intraday basis. In the past week the stock rose 8.42%. stock has been down -32.44% in the past quarter and fell -70.34% in the past year. You can view this in the overview section.